Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarkers of Inflammation and Fibrosis in Conduction Disorders After TAVI
Sponsor: Clinical Hospital Center Rijeka
Summary
Prediction of conduction disorders (CDs) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) is an important and complex process with a significant impact on patient outcomes. The goal of this observational prospective trial is to investigate the role of pre-procedural values of systemic biomarkers of inflammation and fibrosis in the prediction of new-onset CDs and permanent pacemaker implantation (PPI) in patients undergoing the TAVI procedure.
Official title: The Role of Inflammation and Fibrosis in the Development of Conduction Disorders After Transcatheter Aortic Valve Implantation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
102
Start Date
2024-12-12
Completion Date
2026-08
Last Updated
2025-10-06
Healthy Volunteers
Yes
Conditions
Interventions
Biomarkers of inflammation and fibrosis in pre-procedural serum blood samples
In all patients, peripheral venous blood samples will be collected before the TAVI procedure for analysis and calculation of prespecified inflammatory and fibrosis biomarkers. In a subpopulation of 40 individuals, four specific microRNAs (miR-21, miR-29b, miR-155, and miR-146b) will be additionally analysed. The level of each biomarker will be correlated with rates of new-onset TAVI-related CDs and compared between patients with detected and patients without detected new-onset CDs.
Transthoracic echocardiography with myocardial deformation analysis and staging according to the extent of cardiac damage related to AS
The echocardiographic stage of extravalvular cardiac damage related to AS and myocardial deformation parameters will be analysed in each patient before TAVI procedure and compared between the group with detected new-onset CDs and the group without new-onset CDs with a goal to examine their predictive value for the development of TAVI-related CDs.
Locations (1)
Clinical Hospital Center Rijeka
Rijeka, Croatia, Croatia